A research-context examination of Selank’s dose-dependent inhibition of neprilysin and related enkephalin-degrading enzymes, the resulting stabilization of Met-enkephalin in serum assays, and associated dopaminergic and GABA-pathway gene expression changes in preclinical preparations.

A preclinical research overview of Selank’s positive allosteric modulation at the GABA-A benzodiazepine binding site and associated hippocampal transcriptomic responses in rodent models.

Mechanisms Being Explored in Selank Research

← Back to The Cognitive Edge Research Context Selank is a synthetic heptapeptide, meaning it is a chain of seven amino acids assembled in a laboratory setting. Its structural origin is tuftsin, an endogenous tetrapeptide with known immunomodulatory properties, carrying the sequence Thr-Lys-Pro-Arg. Selank extends this base sequence by appending Pro-Gly-Pro to the C-terminal end, […]